On October 5, 2020 Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, reported a two-year strategic partnership with Xilio Therapeutics (Press release, Applied BioMath, OCT 5, 2020, View Source [SID1234568125]). Applied BioMath will provide a variety of services related to mathematical modeling, simulation, analysis, and visualization, which include systems pharmacology, quantitative systems pharmacology, experiment prioritization and design, and traditional and mechanistic pharmacokinetic (PK) / pharmacodynamic (PD) modeling, in support of Xilio’s preclinical and clinical drug development projects. "We are thrilled to announce this next phase of our partnership with Xilio Therapeutics," said John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. "We really enjoy being part of the project teams, working on exciting projects and science, and helping to better inform decisions. We take pride in partnerships such as these as they are evidence that our prior collaborations with our partners provided high value."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Applied BioMath employs a rigorous fit-for-purpose model development process which quantitatively integrates knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms. Applied BioMath’s approach employs proprietary algorithms and software that were designed specifically for systems pharmacology model development, simulation, and analysis. "Our previous collaborations with Applied BioMath informed the advancement of our preclinical candidates," said Jennifer O’Neil, PhD, Vice President, Translational Oncology at Xilio Therapeutics. "We look forward to continuing to work closely with Applied BioMath and incorporate their approach into more of our projects."